Evidence map›Paper›PMID 25143022›Full record

ArticleHIV clinical trials

Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.

Philip M Grant, Lauren Komarow, Alejandro Sanchez, Fred R Sattler, David M Asmuth, Richard B Pollard, Andrew R Zolopa

Open access · greenAbstract read
In one paragraph

Article in HIV clinical trials. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. A Low Frequency of IL-17-Producing CD8Frontiers in immunology · 2018
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Philip M GrantStanford University, Stanford, California.
Lauren KomarowHarvard School of Public Health, Boston, Massachusetts.
Alejandro SanchezKeck School of Medicine, Los Angeles, California.
Fred R SattlerKeck School of Medicine, Los Angeles, California.
David M AsmuthUniversity of California, Davis, Sacramento, California.
Richard B PollardUniversity of California, Davis, Sacramento, California.
Andrew R ZolopaStanford University, Stanford, California.
Stanford University · USUniversity of California, Davis · USUniversity of Southern California · USHarvard University · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitU01AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 2007 to 2011
$19.3M
UNIVERSITY OF SOUTHERN CALIFORNIA CLINICAL TRIALS UNITU01AI069428 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SATTLER, FRED R · 2007 to 2011
$8.5M
Stanford AIDS Clinical Trials UnitU01AI069556 · NIAID · STANFORD UNIVERSITY · PI ZOLOPA, ANDREW RICHARD · 2007 to 2011
$4.3M
UNIVERSITY OF SOUTHERN CALIFORNIA CLINICAL TRIALS UNITUM1AI069428 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SATTLER, FRED R · 2012 to 2013
$3.3M
Stanford AIDS Clinical Trials UnitUM1AI069556 · NIAID · STANFORD UNIVERSITY · PI ZOLOPA, ANDREW RICHARD · 2012 to 2014
$2.0M
NCATS NIH HHS UL1 TR000439NIAID NIH HHS K23 AI108358NIAID NIH HHS K23AI108358NIAID NIH HHS U01 AI068634NIAID NIH HHS U01AI068634NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1AI068636NIAID NIH HHS UM1 AI069428NIAID NIH HHS UM1AI069428NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069556NIAID NIH HHS UM1AI069556NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

backgroundIn the pre-antiretroviral therapy (ART) era, markers of increased disease severity during an acute opportunistic infection (OI) were associated with mortality. Even with ART, mortality remains high during the first year after an OI in persons with advanced HIV infection, but it is unclear whether previous predictors of mortality remain valid in the current era.

objectiveTo determine clinical and immunological predictors of death after an OI.

methodsWe used clinical data and stored plasma from ACTG A5164, a multicenter study evaluating the optimal timing of ART during a nontuberculous OI. We developed Cox models evaluating associations between clinical parameters and plasma marker levels at entry and time to death over the first 48 weeks after the diagnosis of OI. We developed multivariable models incorporating only clinical parameters, only plasma marker levels, or both.

resultsThe median CD4+ T-cell count in study participants at baseline was 29 cells/µL. Sixty-four percent of subjects had Pneumocystis jirovecii pneumonia (PCP). Twenty-three of 282 (8.2%) subjects died. In univariate analyses, entry mycobacterial infection, OI number, hospitalization, low albumin, low hemoglobin, lower CD4, and higher IL-8 and sTNFrII levels and lower IL-17 levels were associated with mortality. In the combined model using both clinical and immunologic parameters, the presence of an entry mycobacterial infection and higher sTNFrII levels were significantly associated with death.

conclusionsIn the ART era, clinical risk factors for death previously identified in the pre-ART era remain predictive. Additionally, activation of the innate immune system is associated with an increased risk of death following an acute OI.

Indexed as

Acquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsFemaleHumansMaleMultivariate AnalysisProportional Hazards ModelsRisk FactorsHIV infections/complicationsmortalityopportunistic infections

Identifiers

PMID25143022
PMCPMC4167015
OpenAlexW2075009523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.